BCOR sirna

BCOR siRNA (Human)

Cat. Num. AAA8205376

• Gene Names: BCOR; MAA2; ANOP2; MCOPS2
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: BCOR; BCOR siRNA (Human); KIAA1575; BCL-6 corepressor; BCoR; BCOR sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: BCOR siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 1721

• Applicable Applications for BCOR sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human BCOR gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for BCOR sirna

siRNA to inhibit BCOR expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 183396783
• NCBI GeneID: 54880
• NCBI Accession #: NP_001116855.1
• NCBI GenBank Nucleotide #: NM_001123383.1
• UniProt Accession #: Q6W2J9; Q29RF6; Q6P4B6; Q7Z2K7; Q8TEB4; Q96DB3; Q9H232; Q9H233; Q9HCJ7; Q9NXF2; D3DWB3; D3DWB4
• Molecular Weight: 186,235 Da
• NCBI Official Full Name: BCL-6 corepressor isoform a
• NCBI Official Synonym Full Names: BCL6 corepressor
• NCBI Official Symbol: BCOR
• NCBI Official Synonym Symbols: MAA2; ANOP2; MCOPS2
• NCBI Protein Information: BCL-6 corepressor
• UniProt Protein Name: BCL-6 corepressor
• Protein Family: BCL-6 corepressor
• UniProt Gene Name: BCOR
• UniProt Synonym Gene Names: KIAA1575; BCoR
• UniProt Entry Name: BCOR_HUMAN

NCBI Description

The protein encoded by this gene was identified as an interacting corepressor of BCL6, a POZ/zinc finger transcription repressor that is required for germinal center formation and may influence apoptosis. This protein selectively interacts with the POZ domain of BCL6, but not with eight other POZ proteins. Specific class I and II histone deacetylases (HDACs) have been shown to interact with this protein, which suggests a possible link between the two classes of HDACs. Several transcript variants encoding different isoforms have been found for this gene. A pseudogene of this gene is found on chromosome Y.[provided by RefSeq, Jun 2010]

Uniprot Description

BCOR: Transcriptional corepressor. May specifically inhibit gene expression when recruited to promoter regions by sequence specific DNA-binding proteins such as BCL6 and MLLT3. This repression may be mediated at least in part by histone deacetylase activities which can associate with this corepressor. Involved in the repression of TFAP2A; impairs binding of BCL6 and KDM2B to TFAP2A promoter regions. Via repression of TFAP2A acts as a negative regulator of osteo-dentiogenic capacity in adult stem cells; the function implies inhibition of methylation on histone H3 'Lys-4' (H3K4me3) and 'Lys-36' (H3K36me2). Defects in BCOR are the cause of microphthalmia syndromic type 2 (MCOPS2). Microphthalmia is a clinically heterogeneous disorder of eye formation, ranging from small size of a single eye to complete bilateral absence of ocular tissues (anophthalmia). In many cases, microphthalmia/anophthalmia occurs in association with syndromes that include non-ocular abnormalities. MCOPS2 is a very rare multiple congenital anomaly syndrome characterized by eye anomalies (congenital cataract, microphthalmia, or secondary glaucoma), facial abnormalities (long narrow face, high nasal bridge, pointed nose with cartilages separated at the tip, cleft palate, or submucous cleft palate), cardiac anomalies (atrial septal defect, ventricular septal defect, or floppy mitral valve) and dental abnormalities (canine radiculomegaly, delayed dentition, oligodontia, persistent primary teeth, or variable root length). Belongs to the BCOR family. 4 isoforms of the human protein are produced by alternative splicing.

Protein type: Transcription, coactivator/corepressor

Chromosomal Location of Human Ortholog: Xp11.4

Cellular Component: PcG protein complex; nucleus

Molecular Function: protein binding; heat shock protein binding; histone deacetylase binding; ubiquitin-protein ligase activity; transcription factor binding; transcription corepressor activity

Biological Process: odontogenesis; negative regulation of bone mineralization; transcription, DNA-dependent; negative regulation of histone H3-K36 methylation; heart development; specification of axis polarity; negative regulation of histone H3-K4 methylation; negative regulation of transcription from RNA polymerase II promoter; palate development; negative regulation of transcription, DNA-dependent

Disease: Microphthalmia, Syndromic 2; Microphthalmia, Syndromic 1